Article in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Shuibang WangCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.ORCID 0000-0002-5076-6763
Keytam S AwadCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.
Li-Yuan ChenCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.ORCID 0000-0002-3596-4577
Mohammad A H SiddiqueCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.
Gabriela A FerreyraCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.ORCID 0000-0002-1225-9939
Caroline L WangCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.
Thea JosephCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.ORCID 0009-0005-1232-746X
Zu-Xi YuNational Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States.
Kazuyo TakedaNational Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States.
Cumhur Y DemirkaleCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.
You-Yang ZhaoSection for Injury Repair and Regeneration, Stanley Manne Children Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States.
Jason M ElinoffCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.ORCID 0000-0002-2376-6370
Robert L DannerCritical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States.ORCID 0000-0001-5715-3823
Funding
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
Novel mechanisms of obliterative pulmonary vascular remodeling and sever pulmonary arterial hypertensionR01HL133951 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ZHAO, YOU-YANG · 2016 to 2024
$4.9M
Cellular Models of PAH-Associated Molecular Defects as a Tool for Identifying New Therapeutic TargetsZIAHL006288 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ELINOFF, JASON · 2023 to 2025
$4.1M
Negative regulators of endothelial regeneration in aging lungs and ARDSR01HL164014 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2022 to 2025
$2.7M
Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAHR01HL162299 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2022 to 2025
$2.6M
Novel mechanisms of endothelial Injury in the pathogenesis of ARDSR01HL148810 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2020 to 2023
$2.3M
Novel intrinsic endothelial stem cells responsible for lung endothelial regeneration and vascular repair in ARDSR01HL172447 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI YOU-YANG ZHAO · 2024 to 2026
In hypoxic and pseudohypoxic rodent models of pulmonary hypertension (PH), hypoxia-inducible factor (HIF) inhibition attenuates disease initiation. However, HIF activation alone, due to genetic alterations or use of inhibitors of prolyl hydroxylase domain (PHD) enzymes, has not been definitively shown to cause PH in humans, indicating the involvement of other mechanisms. Given the association between endothelial cell dysfunction and PH, the effects of pseudohypoxia and its underlying pathways were investigated in primary human lung endothelial cells.
Indexed as
ApoptosisBasic Helix-Loop-Helix ProteinsEndothelial CellsHypertension, PulmonaryHypoxia-Inducible Factor-Proline DioxygenasesProto-Oncogene Proteins c-aktAdaptor Proteins, Signal TransducingAnimalsEndothelial PAS Domain-Containing Protein 1HumansInflammationLungMiceMice, KnockoutSignal TransductionAdaptor Proteins, Signal TransducingBasic Helix-Loop-Helix ProteinsEGLN1 protein, humanEndothelial PAS Domain-Containing Protein 1Hypoxia-Inducible Factor-Proline DioxygenasesProto-Oncogene Proteins c-aktAIP1AKTapoptosisPHD2STAT
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α. · full record | Socratic